Home / Business and Economy / CuraTeQ and BioFactura End Stelara Biosimilar Pact
CuraTeQ and BioFactura End Stelara Biosimilar Pact
27 Dec
Summary
- CuraTeQ, Aurobindo subsidiary, terminates BioFactura license agreement.
- The termination of the biosimilar deal is effective December 27, 2025.
- Decision follows a strategic review and pipeline prioritisation by CuraTeQ.
CuraTeQ Biologics Private Limited, a subsidiary of Aurobindo Pharma Limited, has mutually agreed to end its license agreement with BioFactura Inc. This agreement was for the commercialization of BFI-751, a proposed biosimilar of ustekinumab, commonly known as Stelara. The decision to terminate the pact, which was initially established in July 2023, stems from a strategic review and CuraTeQ's ongoing efforts to prioritize its product pipeline. Under the original terms, BioFactura was to receive development and commercial milestone-linked license fees, while CuraTeQ held global manufacturing rights with a profit-sharing arrangement. This termination, effective December 27, 2025, is expected to have no significant impact on Aurobindo Pharma's overall biosimilars strategy or its long-term growth plans. The company emphasized that BioFactura is not related to its promoters, ensuring the transaction is not a related-party dealing. CuraTeQ remains focused on optimizing its biosimilars pipeline.
